Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology - United States
doi 10.1002/ana.21676
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Wiley

Related search

Identification of Approval Conditions for Orphan Drugs for Neurological Disorders by the Japanese Regulatory Agency

Expert Opinion on Orphan Drugs
ToxicologyPharmaceuticsPharmacologyHealth Policy
2018English

Hta Studies on Orphan Drugs by Rebratsxmembers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Analysis of the Ultra-Orphan Drugs Approved by the Fda in the Period 1983-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

The First Experiences With Reassessments and Appraisals of Conditionally Approved Expensive and Orphan Drugs in the Netherlands (2006-2013)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Repurposing FDA-approved Drugs for Anti-Aging Therapies

Biogerontology
AgingGerontologyGeriatrics
2016English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

New Drugs for Mental Diseases?: New Diseases for Old Drugs?

Journal of the Royal Society of Medicine
Medicine
1987English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy